Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 5, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2015-08-13
DOI
10.3389/fonc.2015.00183
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- miR-203 inhibits melanoma invasive and proliferative abilities by targeting the polycomb group gene BMI1
- (2015) Xiao Chang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting drivers of melanoma with synthetic small molecules and phytochemicals
- (2015) Leah Ray Strickland et al. CANCER LETTERS
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Cell cycle control as a promising target in melanoma
- (2015) Belinda Lee et al. CURRENT OPINION IN ONCOLOGY
- Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
- (2015) Igor Puzanov et al. EUROPEAN JOURNAL OF CANCER
- Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
- (2015) Alan E. Siroy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.
- (2015) Mickaël Ohanna et al. Oncotarget
- Beyond BRAF: where next for melanoma therapy?
- (2014) I V Fedorenko et al. BRITISH JOURNAL OF CANCER
- Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
- (2014) Chang Xia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
- (2014) Moriah H. Nissan et al. CANCER RESEARCH
- Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
- (2014) K. Kemper et al. CANCER RESEARCH
- SWI/SNF Chromatin Remodeling Enzymes in Melanocyte Differentiation and Melanoma
- (2014) A. Mehrotra et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Oncogenes in melanoma: An update
- (2014) Manfred Kunz EUROPEAN JOURNAL OF CELL BIOLOGY
- Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma
- (2014) Judy W King et al. Future Oncology
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
- (2014) K. G. Griewank et al. JNCI-Journal of the National Cancer Institute
- AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
- (2014) Emilia Caputo et al. Journal of Translational Medicine
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
- (2014) Paolo A Ascierto et al. Journal of Translational Medicine
- Discrepant alterations in main candidate genes among multiple primary melanomas
- (2014) Maria Colombino et al. Journal of Translational Medicine
- Systemic treatment for BRAF-mutant melanoma: where do we go next?
- (2014) Alexander M Menzies et al. LANCET ONCOLOGY
- Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
- (2014) Matteo S. Carlino et al. Molecular Oncology
- Genome-wide analysis of noncoding regulatory mutations in cancer
- (2014) Nils Weinhold et al. NATURE GENETICS
- POT1 loss-of-function variants predispose to familial melanoma
- (2014) Carla Daniela Robles-Espinoza et al. NATURE GENETICS
- Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
- (2014) Jianxin Shi et al. NATURE GENETICS
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is it time to test biguanide metformin in the treatment of melanoma?
- (2014) Michael Cerezo et al. Pigment Cell & Melanoma Research
- EZH2: an emerging role in melanoma biology and strategies for targeted therapy
- (2014) Jessamy Tiffen et al. Pigment Cell & Melanoma Research
- The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
- (2014) J. A. Lo et al. SCIENCE
- Profile of selumetinib and its potential in the treatment of melanoma
- (2014) Sapna Patel et al. OncoTargets and Therapy
- EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
- (2014) B. Miao et al. Cancer Discovery
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype
- (2014) K. H. T. Paraiso et al. Cancer Discovery
- Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis
- (2014) Deepika Neelakantan et al. Cell Adhesion & Migration
- Clinical characteristics and outcomes with specificBRAFandNRASmutations in patients with metastatic melanoma
- (2013) Amanda D. Bucheit et al. CANCER
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
- (2013) Alexander Roesch et al. CANCER CELL
- Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
- (2013) E. Romano et al. CLINICAL CANCER RESEARCH
- Targeting BRAF in melanoma: Biological and clinical challenges
- (2013) Mario Mandalà et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- New developments in biomarkers for melanoma
- (2013) Klaus G. Griewank et al. CURRENT OPINION IN ONCOLOGY
- Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
- (2013) Jonathan L. Curry et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- A STATement on Vemurafenib-Resistant Melanoma
- (2013) Edward J. Hartsough et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas
- (2013) Fang Liu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
- (2013) Maria Colombino et al. Journal of Translational Medicine
- Which drug, and when, for patients with BRAF-mutant melanoma?
- (2013) Sekwon Jang et al. LANCET ONCOLOGY
- The FBXO4 Tumor Suppressor Functions as a Barrier to BrafV600E-Dependent Metastatic Melanoma
- (2013) Eric K. Lee et al. MOLECULAR AND CELLULAR BIOLOGY
- Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
- (2013) M. S. Carlino et al. MOLECULAR CANCER THERAPEUTICS
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
- (2013) T M Becker et al. ONCOGENE
- MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines
- (2013) A Vultur et al. ONCOGENE
- Context-specific regulation of cancer epigenomes by histone and transcription factor methylation
- (2013) M Sarris et al. ONCOGENE
- Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma
- (2013) P. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TERT Promoter Mutations in Familial and Sporadic Melanoma
- (2013) S. Horn et al. SCIENCE
- Highly Recurrent TERT Promoter Mutations in Human Melanoma
- (2013) F. W. Huang et al. SCIENCE
- MEK Inhibition in the Treatment of Advanced Melanoma
- (2013) April K. S. Salama et al. Current Oncology Reports
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Regulation of MMPs During Melanoma Progression: From Genetic to Epigenetic
- (2012) Antonicelli Frank et al. Anti-Cancer Agents in Medicinal Chemistry
- Melanoma and Epigenetic Treatment: Past and Future
- (2012) Caterina AM La Porta Anti-Cancer Agents in Medicinal Chemistry
- Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune
- (2012) Karin van den Hurk et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Epigenetic biomarkers in skin cancer
- (2012) Edward S. Greenberg et al. CANCER LETTERS
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth
- (2012) Deniz A. Ucar et al. CELL CYCLE
- Aurora A kinase (AURKA) in normal and pathological cell division
- (2012) Anna S. Nikonova et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
- (2012) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Pattern formation in centrosome assembly
- (2012) Robert Mahen et al. CURRENT OPINION IN CELL BIOLOGY
- Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
- (2012) Vipin Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
- (2012) Michele Carbone et al. Journal of Translational Medicine
- AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway
- (2012) Carlotta Petti et al. MELANOMA RESEARCH
- JARID1B expression in human melanoma and benign melanocytic skin lesions
- (2012) Łukasz Kuźbicki et al. MELANOMA RESEARCH
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
- (2012) Luis A. Diaz Jr et al. NATURE
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
- (2012) I V Fedorenko et al. ONCOGENE
- ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
- (2012) A P Rebocho et al. ONCOGENE
- Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
- (2012) Molly Yancovitz et al. PLoS One
- Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
- (2012) Heike Niessner et al. Cancer Medicine
- Expression of the c-Met Proteins in Malignant Skin Cancers
- (2011) Yoon-Jin Lee et al. Annals of Dermatology
- STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
- (2011) B. Dai et al. CANCER RESEARCH
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling
- (2011) J. Chen et al. CANCER RESEARCH
- In vitro and in vivo anti-melanoma action of metformin
- (2011) Kristina Janjetovic et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
- (2011) Franziska Niehr et al. Journal of Translational Medicine
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Targeting the epigenome for treatment of cancer
- (2011) E-J Geutjes et al. ONCOGENE
- Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
- (2011) W. Deng et al. Pigment Cell & Melanoma Research
- Met Receptor: A Moving Target
- (2011) M. J. Clague Science Signaling
- Metformin inhibits melanoma development through autophagy and apoptosis mechanisms
- (2011) T Tomic et al. Cell Death & Disease
- AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival
- (2010) Jennifer Woodard et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
- (2010) M. Pollak Cancer Prevention Research
- Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells
- (2010) I. Ben Sahra et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Overview of macroautophagy regulation in mammalian cells
- (2010) Maryam Mehrpour et al. CELL RESEARCH
- Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy
- (2010) A. G. Sikora et al. CLINICAL CANCER RESEARCH
- Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
- (2010) Thomas F Gajewski et al. CURRENT OPINION IN IMMUNOLOGY
- Mutation-driven drug development in melanoma
- (2010) Keith T Flaherty et al. CURRENT OPINION IN ONCOLOGY
- AMPK as a metabolic tumor suppressor: control of metabolism and cell growth
- (2010) Zhijun Luo et al. Future Oncology
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Cancer stem cells versus phenotype-switching in melanoma
- (2010) Keith S. Hoek et al. Pigment Cell & Melanoma Research
- A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
- (2010) Marie C. Zipser et al. Pigment Cell & Melanoma Research
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment
- (2010) Russell R. Braeuer et al. SEMINARS IN CANCER BIOLOGY
- Genetic risk factors for melanoma
- (2009) Kathrine Damm Meyle et al. HUMAN GENETICS
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
- (2009) Keiran S.M. Smalley JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Polyclonality of BRAF Mutations in Acquired Melanocytic Nevi
- (2009) Jingrong Lin et al. JNCI-Journal of the National Cancer Institute
- Main roads to melanoma
- (2009) Giuseppe Palmieri et al. Journal of Translational Medicine
- Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA
- (2009) K.-H. Lim et al. MOLECULAR AND CELLULAR BIOLOGY
- Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
- (2009) Bijay S. Jaiswal et al. PLoS One
- A multi-marker assay to distinguish malignant melanomas from benign nevi
- (2009) M. Kashani-Sabet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- How Shelterin Protects Mammalian Telomeres
- (2008) Wilhelm Palm et al. Annual Review of Genetics
- The Aurora kinase family in cell division and cancer
- (2008) Gerben Vader et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- RAS: Target for Cancer Therapy
- (2008) Nandita Saxena et al. CANCER INVESTIGATION
- In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
- (2008) K. S. Hoek et al. CANCER RESEARCH
- Autophagy in the Pathogenesis of Disease
- (2008) Beth Levine et al. CELL
- Control of autophagy by oncogenes and tumor suppressor genes
- (2008) M C Maiuri et al. CELL DEATH AND DIFFERENTIATION
- KIT Gene Mutations and Copy Number in Melanoma Subtypes
- (2008) C. Beadling et al. CLINICAL CANCER RESEARCH
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
- Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
- (2008) Satoru Yokoyama et al. Pigment Cell & Melanoma Research
- The role of p53 in pigmentation, tanning and melanoma
- (2008) Neil F. Box et al. Pigment Cell & Melanoma Research
- Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
- (2008) Claudia Wellbrock et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now